<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00474240</url>
  </required_header>
  <id_info>
    <org_study_id>AEGR-733-003</org_study_id>
    <nct_id>NCT00474240</nct_id>
  </id_info>
  <brief_title>AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aegerion Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aegerion Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effectiveness of the study drug, AEGR-733 alone and
      in combination with the medication, atorvastatin (Lipitor), on cholesterol in volunteers with
      moderately high cholesterol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent studies suggest more intensive cholesterol lowering treatment for people at very high
      risk of a heart attack, specifically for patients who have heart disease plus major risk
      factors. Available medications used alone at even the highest approved doses are not expected
      to reach these new target recommendations for cholesterol in a large number of subjects.
      Thus, the development of new medications that can provide additional cholesterol lowering may
      be beneficial.

      This study tests the effectiveness of different doses of the study drug, AEGR-733 alone and
      in combination with the approved cholesterol lowering drug, atorvastatin (Lipitor), on
      cholesterol. Volunteers will be randomized to one of 6 different study treatments and will
      take the assigned medication (3 capsules daily) for 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in LDL-C at 8 Weeks</measure>
    <time_frame>Atfer 8 weeks on study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline of Other Lipids</measure>
    <time_frame>After 8 weeks of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20 mg</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEGR-733 5 mg</intervention_name>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEGR-733 10 mg</intervention_name>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEGR-733 5 mg + atorvastatin 20 mg</intervention_name>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEGR-733 10 mg + atorvastatin 20 mg</intervention_name>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women between the ages of 18 and 70 years.

          2. Elevated LDL cholesterol based on risk factors for cardiovascular disease or presence
             of cardiovascular disease

        Exclusion Criteria:

          1. Women who are pregnant, lactating, planning to become pregnant, or women of
             childbearing potential who have not successfully been using acceptable contraceptive
             methods over the previous 3 months, e.g., intrauterine device (IUD) and barrier method
             plus spermicide.

          2. Uncontrolled hypertension

          3. History of chronic kidney problems

          4. History of liver disease

          5. Positive for Hepatitis B or Hepatitis C.

          6. Any major surgical procedure occurring less than 3 months ago

          7. Cardiac insufficiency

          8. History of a malignant cancer (other than basal cell or squamous cell carcinoma of the
             skin that has been removed) within the previous 5 years.

          9. Regular alcohol use &gt;1 drink per day.

         10. Regular consumers of grapefruit juice, or currently taking the following medications:
             cyclosporine, itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin,
             HIV protease inhibitors, and nefazodone.

         11. Use of other cholesterol lowering medications that cannot be stopped.

         12. Heart attack or stroke within the previous 6 months

         13. Diabetes Mellitus

         14. Body mass index (BMI) â‰¥ 40 kg/m2.

         15. Significant gastrointestinal symptoms, such as irritable bowel syndrome.

         16. Current use of fish oils, niacin, and herbal weight loss products that cannot be
             stopped.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Affiliated Research Center</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center For Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Georgia Clinical Research</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medsphere Medical Research Center</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute for Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Research Associates</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Trends Research</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Medical Research Associates</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Goose Creek</city>
        <state>South Carolina</state>
        <zip>29445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes and Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes and Glandular Disease Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hampton Roads Center for Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE, Rader DJ. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007 Jan 11;356(2):148-56.</citation>
    <PMID>17215532</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2007</study_first_submitted>
  <study_first_submitted_qc>May 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2007</study_first_posted>
  <results_first_submitted>January 18, 2013</results_first_submitted>
  <results_first_submitted_qc>January 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 21, 2013</results_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was performed from 05 November 2007 to 04 August 2008 at 17 medical clinics within the United States.</recruitment_details>
      <pre_assignment_details>Subjects who were previously on a lipid lowering therapy underwent a 5-week washout period. All subjects were on a low-fat diet (&lt;30% calories from fat) starting 5 weeks prior to study drug treatment and continuing for the duration of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo capsule taken orally once daily</description>
        </group>
        <group group_id="P2">
          <title>Atorvastatin 20 mg</title>
          <description>Atorvastatin 20 mg taken orally once daily</description>
        </group>
        <group group_id="P3">
          <title>AEGR-733 5 mg</title>
          <description>AEGR-733 5 mg taken orally once daily</description>
        </group>
        <group group_id="P4">
          <title>AEGR-733 10 mg</title>
          <description>AEGR-733 10 mg taken orally once daily</description>
        </group>
        <group group_id="P5">
          <title>AEGR-733 5 mg + Atorvastatin 20 mg</title>
          <description>One capsule of AEGR-733 5 mg and 1 capsule of Atorvastatin 20 mg taken orally once daily</description>
        </group>
        <group group_id="P6">
          <title>AEGR-733 10 mg + Atorvastatin 20 mg</title>
          <description>One capsule of AEGR-733 10 mg and 1 capsule of Atorvastatin 20 mg taken orally once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="26"/>
                <participants group_id="P6" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Removed due to lab value</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo capsule taken orally once daily</description>
        </group>
        <group group_id="B2">
          <title>Atorvastatin 20 mg</title>
          <description>Atorvastatin 20 mg taken orally once daily</description>
        </group>
        <group group_id="B3">
          <title>AEGR-733 5 mg</title>
          <description>AEGR-733 5 mg taken orally once daily</description>
        </group>
        <group group_id="B4">
          <title>AEGR-733 10 mg</title>
          <description>AEGR-733 10 mg taken orally once daily</description>
        </group>
        <group group_id="B5">
          <title>AEGR-733 5 mg + Atorvastatin 20 mg</title>
          <description>One capsule of AEGR-733 5 mg and 1 capsule of Atorvastatin 20 mg taken orally once daily</description>
        </group>
        <group group_id="B6">
          <title>AEGR-733 10 mg + Atorvastatin 20 mg</title>
          <description>One capsule of AEGR-733 10 mg and 1 capsule of Atorvastatin 20 mg taken orally once daily</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="26"/>
            <count group_id="B5" value="26"/>
            <count group_id="B6" value="26"/>
            <count group_id="B7" value="157"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="11.1"/>
                    <measurement group_id="B2" value="56" spread="8.4"/>
                    <measurement group_id="B3" value="56" spread="8.3"/>
                    <measurement group_id="B4" value="54" spread="11.6"/>
                    <measurement group_id="B5" value="51" spread="10.1"/>
                    <measurement group_id="B6" value="53" spread="9.7"/>
                    <measurement group_id="B7" value="54" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in LDL-C at 8 Weeks</title>
        <time_frame>Atfer 8 weeks on study drug</time_frame>
        <population>Intent To Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsule taken orally once daily</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Atorvastatin 20 mg taken orally once daily</description>
          </group>
          <group group_id="O3">
            <title>AEGR-733 5 mg</title>
            <description>AEGR-733 5 mg taken orally once daily</description>
          </group>
          <group group_id="O4">
            <title>AEGR-733 10 mg</title>
            <description>AEGR-733 10 mg taken orally once daily</description>
          </group>
          <group group_id="O5">
            <title>AEGR-733 5 mg + Atorvastatin 20 mg</title>
            <description>One capsule of AEGR-733 5 mg and 1 capsule of Atorvastatin 20 mg taken orally once daily</description>
          </group>
          <group group_id="O6">
            <title>AEGR-733 10 mg + Atorvastatin 20 mg</title>
            <description>One capsule of AEGR-733 10 mg and 1 capsule of Atorvastatin 20 mg taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in LDL-C at 8 Weeks</title>
          <population>Intent To Treat</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="11.2"/>
                    <measurement group_id="O2" value="-42" spread="16.4"/>
                    <measurement group_id="O3" value="-16" spread="17.3"/>
                    <measurement group_id="O4" value="-37" spread="23.0"/>
                    <measurement group_id="O5" value="-47" spread="19.2"/>
                    <measurement group_id="O6" value="-50" spread="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline of Other Lipids</title>
        <time_frame>After 8 weeks of study drug</time_frame>
        <population>Intent To Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsule taken orally once daily</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Atorvastatin 20 mg taken orally once daily</description>
          </group>
          <group group_id="O3">
            <title>AEGR-733 5 mg</title>
            <description>AEGR-733 5 mg taken orally once daily</description>
          </group>
          <group group_id="O4">
            <title>AEGR-733 10 mg</title>
            <description>AEGR-733 10 mg taken orally once daily</description>
          </group>
          <group group_id="O5">
            <title>AEGR-733 5 mg + Atorvastatin 20 mg</title>
            <description>One capsule of AEGR-733 5 mg and 1 capsule of Atorvastatin 20 mg taken orally once daily</description>
          </group>
          <group group_id="O6">
            <title>AEGR-733 10 mg + Atorvastatin 20 mg</title>
            <description>One capsule of AEGR-733 10 mg and 1 capsule of Atorvastatin 20 mg taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline of Other Lipids</title>
          <population>Intent To Treat</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change from baseline in total cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="9.9"/>
                    <measurement group_id="O2" value="-30" spread="12.4"/>
                    <measurement group_id="O3" value="-18" spread="14.6"/>
                    <measurement group_id="O4" value="-33" spread="19.0"/>
                    <measurement group_id="O5" value="-37" spread="15.3"/>
                    <measurement group_id="O6" value="-40" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change from baseline in total Apo B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="11.0"/>
                    <measurement group_id="O2" value="-34" spread="13.0"/>
                    <measurement group_id="O3" value="-17" spread="12.4"/>
                    <measurement group_id="O4" value="-36" spread="21.9"/>
                    <measurement group_id="O5" value="-41" spread="16.9"/>
                    <measurement group_id="O6" value="-46" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change from baseline in non-HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="10.3"/>
                    <measurement group_id="O2" value="-38" spread="15.8"/>
                    <measurement group_id="O3" value="-19" spread="17.1"/>
                    <measurement group_id="O4" value="-36" spread="26.0"/>
                    <measurement group_id="O5" value="-45" spread="17.7"/>
                    <measurement group_id="O6" value="-48" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo capsule taken orally once daily</description>
        </group>
        <group group_id="E2">
          <title>Atorvastatin 20 mg</title>
          <description>Atorvastatin 20 mg taken orally once daily</description>
        </group>
        <group group_id="E3">
          <title>AEGR-733 5 mg</title>
          <description>AEGR-733 5 mg taken orally once daily</description>
        </group>
        <group group_id="E4">
          <title>AEGR-733 10 mg</title>
          <description>AEGR-733 10 mg taken orally once daily</description>
        </group>
        <group group_id="E5">
          <title>AEGR-733 5 mg + Atorvastatin 20 mg</title>
          <description>One capsule of AEGR-733 5 mg and 1 capsule of Atorvastatin 20 mg taken orally once daily</description>
        </group>
        <group group_id="E6">
          <title>AEGR-733 10 mg + Atorvastatin 20 mg</title>
          <description>One capsule of AEGR-733 10 mg and 1 capsule of Atorvastatin 20 mg taken orally once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="26"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="26"/>
                <counts group_id="E5" events="11" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E6" events="20" subjects_affected="20" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E6" events="14" subjects_affected="14" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Gastric Dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hepatice Enzyme Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Blood Urine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Blood Potassium Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Information is unavailable.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study AEGR-733-003, initiated in May 2007, was halted, and restarted under an amended Protocol in November 2007.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Aegerion Pharmaceuticals</organization>
      <phone>617-500-7867</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

